메뉴 건너뛰기




Volumn 50, Issue 11, 2009, Pages 1848-1853

Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin

Author keywords

Acute myeloid leukemia; Chemotherapy; Etoposide; Mitoxantrone; Prognostic factors

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

EID: 71049137654     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903216788     Document Type: Article
Times cited : (9)

References (22)
  • 1
    • 23644455476 scopus 로고    scopus 로고
    • Drug therapy for acute myeloid leukemia
    • Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
    • (2005) Blood , vol.106 , pp. 1154-1163
    • Tallman, M.S.1    Gilliland, D.G.2    Rowe, J.M.3
  • 3
  • 4
    • 0028009840 scopus 로고
    • Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine
    • Dutch Hematology -Oncology Working Group for Adults (HOVON)
    • Daenen S, Lowenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology -Oncology Working Group for Adults (HOVON). Leukemia 1994;8:6-10.
    • (1994) Leukemia , vol.8 , pp. 6-10
    • Daenen, S.1    Lowenberg, B.2    Sonneveld, P.3
  • 5
    • 0025061187 scopus 로고
    • Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia
    • Ehninger G, Fackler-Schwalbe E, Freund M, et al. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Haematol Blood Transfus 1990;33:316-317.
    • (1990) Haematol Blood Transfus , vol.33 , pp. 316-317
    • Ehninger, G.1    Fackler-Schwalbe, E.2    Freund, M.3
  • 6
    • 0023873515 scopus 로고
    • Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - An active and welltolerated regimen
    • Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - an active and welltolerated regimen. J Clin Oncol 1988;6:213-217.
    • (1988) J Clin Oncol , vol.6 , pp. 213-217
    • Ho, A.D.1    Lipp, T.2    Ehninger, G.3    Illiger, H.J.4    Meyer, P.5    Freund, M.6    Hunstein, W.7
  • 7
    • 0028346958 scopus 로고
    • Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia
    • Knauf WU, Berdel WE, Ho AD, Kreuser ED, Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994;12:421-425.
    • (1994) Leuk Lymphoma , vol.12 , pp. 421-425
    • Knauf, W.U.1    Berdel, W.E.2    Ho, A.D.3    Kreuser, E.D.4    Thiel, E.5
  • 8
    • 0024918203 scopus 로고
    • Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia
    • LazzarinoM,Morra E, Alessandrino EP, et al.Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989;43:411-416.
    • (1989) Eur J Haematol , vol.43 , pp. 411-416
    • Lazzarinommorra, E.1    Alessandrino, E.P.2
  • 9
    • 0025994717 scopus 로고
    • Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia
    • O'Brien S, Kantarjian H, Estey E, et al. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991;68:691-694.
    • (1991) Cancer , vol.68 , pp. 691-694
    • O'Brien, S.1    Kantarjian, H.2    Estey, E.3
  • 10
    • 0025250622 scopus 로고
    • Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia
    • Paciucci PA, Davis RB, Holland JF, Martelo O, Schiffer CA. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol 1990;13:516-519.
    • (1990) Am J Clin Oncol , vol.13 , pp. 516-519
    • Paciucci, P.A.1    Davis, R.B.2    Holland, J.F.3    Martelo, O.4    Schiffer, C.A.5
  • 11
    • 0034672269 scopus 로고    scopus 로고
    • Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia
    • A Southwest Oncology Group/Eastern Cooperative Oncology Group Study
    • Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
    • (2000) Blood , vol.96 , pp. 4075-4083
    • Slovak, M.L.1    Kopecky, K.J.2    Cassileth, P.A.3
  • 12
    • 1542753559 scopus 로고    scopus 로고
    • Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
    • (2003) J Clin Oncol , vol.21 , pp. 4642-4649
    • Cheson, B.D.1    Bennett, J.M.2    Kopecky, K.J.3
  • 13
    • 0026754295 scopus 로고
    • Bonemarrowtransplants may cure patients with acute leukemia never achieving remission with chemotherapy
    • Biggs JC,HorowitzMM,GaleRP, et al.Bonemarrowtransplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992;80:1090-1093.
    • (1992) Blood , vol.80 , pp. 1090-1093
    • Biggs, J.C.1    Horowitz, M.M.2    Gale, R.P.3
  • 14
    • 0742306141 scopus 로고    scopus 로고
    • A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome
    • Fung HC, Stein A, Slovak M, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003;9:766-771.
    • (2003) Biol Blood Marrow Transplant , vol.9 , pp. 766-771
    • Fung, H.C.1    Stein, A.2    Slovak, M.3
  • 15
    • 23744476091 scopus 로고    scopus 로고
    • Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    • DOI 10.1038/sj.bmt.1705038
    • Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 2005;36:183-191. (Pubitemid 41136289)
    • (2005) Bone Marrow Transplantation , vol.36 , Issue.3 , pp. 183-191
    • Song, K.W.1    Lipton, J.2
  • 16
    • 0005040904 scopus 로고    scopus 로고
    • A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia.
    • AML Collaborative Group
    • A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103:100-109.
    • (1998) Br J Haematol , vol.103 , pp. 100-109
  • 17
    • 0021748267 scopus 로고
    • A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia
    • An Eastern Cooperative Oncology Group study
    • Bennett JM, Lymann GH, Cassileth PA, Glick JH, Oken MM. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1984;7:471-473.
    • (1984) Am J Clin Oncol , vol.7 , pp. 471-473
    • Bennett, J.M.1    Lymann, G.H.2    Cassileth, P.A.3    Glick, J.H.4    Oken, M.M.5
  • 21
    • 0034920126 scopus 로고    scopus 로고
    • Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy
    • A report from the BGMT Study Group
    • Jourdan E, Reiffers J, Stoppa AM, et al. Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: A report from the BGMT Study Group. Leuk Lymphoma 2001;42:57-65.
    • (2001) Leuk Lymphoma , vol.42 , pp. 57-65
    • Jourdan, E.1    Reiffers, J.2    Stoppa, A.M.3
  • 22
    • 0030059444 scopus 로고    scopus 로고
    • Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first
    • Anderlini P, Ghaddar HM, Smith TL, et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996;10:964-969.
    • (1996) Leukemia , vol.10 , pp. 964-969
    • Anderlini, P.1    Ghaddar, H.M.2    Smith, T.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.